메뉴 건너뛰기




Volumn 8, Issue 3, 2010, Pages 344-362

Aliskiren, a direct renin inhibitor, in clinical practice: A new approach in the treatment of hypertension

Author keywords

(pro)renin receptors; Aliskiren; Direct renin inhibitors; Hypertension; Renin angiotensin aldosterone system

Indexed keywords

ALDOSTERONE; ALISKIREN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; ATENOLOL; ATORVASTATIN; BRADYKININ; CAPTOPRIL; CELECOXIB; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FENOFIBRATE; HYDROCHLOROTHIAZIDE; IRBESARTAN; KETOCONAZOLE; LISINOPRIL; LOSARTAN; METFORMIN; METOPROLOL; MEVINOLIN; NITRIC OXIDE; PIOGLITAZONE; PLACEBO; RAMIPRIL; ROSIGLITAZONE; STREPTOZOCIN; UNINDEXED DRUG; VALSARTAN;

EID: 77952921915     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016110791112322     Document Type: Article
Times cited : (12)

References (142)
  • 1
    • 22844448780 scopus 로고    scopus 로고
    • Hypertension in adults across the age spectrum: Current outcomes and control in the community
    • Lloyd-Jones DM, Evans JC, Levy D. Hypertension in adults across the age spectrum: current outcomes and control in the community. JAMA 2005; 294: 466-72.
    • (2005) JAMA , vol.294 , pp. 466-472
    • Lloyd-Jones, D.M.1    Evans, J.C.2    Levy, D.3
  • 2
    • 9144248446 scopus 로고    scopus 로고
    • Hypertension treatment and control in five European countries, Canada, and the United States
    • Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-7.
    • (2004) Hypertension , vol.43 , pp. 10-17
    • Wolf-Maier, K.1    Cooper, R.S.2    Kramer, H.3
  • 3
    • 0038460302 scopus 로고    scopus 로고
    • The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report
    • Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 2003; 289: 2560-72.
    • (2003) JAMA , vol.289 , pp. 2560-2572
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 4
    • 0023786331 scopus 로고
    • Molecular biology of the reninangiotensin system
    • Dzau VJ, Burt DW, Pratt RE. Molecular biology of the reninangiotensin system. Am J Physiol 1988; 255: F563-73.
    • (1988) Am J Physiol , vol.255
    • Dzau, V.J.1    Burt, D.W.2    Pratt, R.E.3
  • 5
    • 0036535405 scopus 로고    scopus 로고
    • The angiotensin-converting enzyme gene family: Genomics and pharmacology
    • Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 2002; 23: 177-83.
    • (2002) Trends Pharmacol Sci , vol.23 , pp. 177-183
    • Turner, A.J.1    Hooper, N.M.2
  • 7
    • 0026069821 scopus 로고
    • Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia
    • Dzau VJ, Gibbons GH, Pratt RE. Molecular mechanisms of vascular renin-angiotensin system in myointimal hyperplasia. Hypertension 1991; 18: II100-5.
    • (1991) Hypertension , vol.18
    • Dzau, V.J.1    Gibbons, G.H.2    Pratt, R.E.3
  • 8
    • 0027160183 scopus 로고
    • Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II
    • Itoh H, Mukoyama M, Pratt RE, Gibbons GH, Dzau VJ. Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 1993; 91: 2268-74.
    • (1993) J Clin Invest , vol.91 , pp. 2268-2274
    • Itoh, H.1    Mukoyama, M.2    Pratt, R.E.3    Gibbons, G.H.4    Dzau, V.J.5
  • 9
    • 0035573901 scopus 로고    scopus 로고
    • Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: A possible role for interleukin-6
    • Keidar S, Heinrich R, Kaplan M, Hayek T, Aviram M. Angiotensin II administration to atherosclerotic mice increases macrophage uptake of oxidized LDL: a possible role for interleukin-6. Arterioscler Thromb Vasc Biol 2001; 21: 1464-9.
    • (2001) Arterioscler Thromb Vasc Biol , vol.21 , pp. 1464-1469
    • Keidar, S.1    Heinrich, R.2    Kaplan, M.3    Hayek, T.4    Aviram, M.5
  • 10
    • 0027968595 scopus 로고
    • Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme
    • Morishita R, Gibbons GH, Ellison KE, et al. Evidence for direct local effect of angiotensin in vascular hypertrophy. In vivo gene transfer of angiotensin converting enzyme. J Clin Invest 1994; 94: 978-84.
    • (1994) J Clin Invest , vol.94 , pp. 978-984
    • Morishita, R.1    Gibbons, G.H.2    Ellison, K.E.3
  • 11
    • 0031811033 scopus 로고    scopus 로고
    • Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure
    • Su EJ, Lombardi DM, Siegal J, Schwartz SM. Angiotensin II induces vascular smooth muscle cell replication independent of blood pressure. Hypertension 1998; 31: 1331-7.
    • (1998) Hypertension , vol.31 , pp. 1331-1337
    • Su, E.J.1    Lombardi, D.M.2    Siegal, J.3    Schwartz, S.M.4
  • 12
    • 0030807119 scopus 로고    scopus 로고
    • Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells
    • Nishimura H, Tsuji H, Masuda H, et al. Angiotensin II increases plasminogen activator inhibitor-1 and tissue factor mRNA expression without changing that of tissue type plasminogen activator or tissue factor pathway inhibitor in cultured rat aortic endothelial cells. Thromb Haemost 1997; 77: 1189-95.
    • (1997) Thromb Haemost , vol.77 , pp. 1189-1195
    • Nishimura, H.1    Tsuji, H.2    Masuda, H.3
  • 13
    • 33646792585 scopus 로고    scopus 로고
    • Renal and vascular hypertension-induced inflammation: Role of angiotensin II
    • Ruiz-Ortega M, Esteban V, Ruperez M, et al. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 2006; 15: 159-66.
    • (2006) Curr Opin Nephrol Hypertens , vol.15 , pp. 159-166
    • Ruiz-Ortega, M.1    Esteban, V.2    Ruperez, M.3
  • 14
    • 0034024638 scopus 로고    scopus 로고
    • Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice
    • Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 2000; 35: 985-91.
    • (2000) Hypertension , vol.35 , pp. 985-991
    • Mazzolai, L.1    Pedrazzini, T.2    Nicoud, F.3    Gabbiani, G.4    Brunner, H.R.5    Nussberger, J.6
  • 15
    • 1542374750 scopus 로고    scopus 로고
    • Evidence for a local angiotensingenerating system and dose-dependent inhibition of glucosestimulated insulin release by angiotensin II in isolated pancreatic islets
    • Lau T, Carlsson PO, Leung PS. Evidence for a local angiotensingenerating system and dose-dependent inhibition of glucosestimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 2004; 47: 240-8.
    • (2004) Diabetologia , vol.47 , pp. 240-248
    • Lau, T.1    Carlsson, P.O.2    Leung, P.S.3
  • 17
    • 58549083401 scopus 로고    scopus 로고
    • Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors
    • Ognibene DT, Oliveira PR, Marins de Carvalho LC, et al. Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors. Clin Exp Pharmacol Physiol 2009; 36: 12-9.
    • (2009) Clin Exp Pharmacol Physiol , vol.36 , pp. 12-19
    • Ognibene, D.T.1    Oliveira, P.R.2    Marins de Carvalho, L.C.3
  • 18
    • 36348982705 scopus 로고    scopus 로고
    • Emerging concepts of regulation of angiotensin II receptors: New players and targets for traditional receptors
    • Mogi M, Iwai M, Horiuchi M. Emerging concepts of regulation of angiotensin II receptors: new players and targets for traditional receptors. Arterioscler Thromb Vasc Biol 2007; 27: 2532-9.
    • (2007) Arterioscler Thromb Vasc Biol , vol.27 , pp. 2532-2539
    • Mogi, M.1    Iwai, M.2    Horiuchi, M.3
  • 19
    • 0034601761 scopus 로고    scopus 로고
    • Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice
    • Akishita M, Iwai M, Wu L, et al. Inhibitory effect of angiotensin II type 2 receptor on coronary arterial remodeling after aortic banding in mice. Circulation 2000; 102: 1684-9.
    • (2000) Circulation , vol.102 , pp. 1684-1689
    • Akishita, M.1    Iwai, M.2    Wu, L.3
  • 20
    • 0035902572 scopus 로고    scopus 로고
    • Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin IIinduced hypertension
    • Ichihara S, Senbonmatsu T, Price E, Jr., Ichiki T, Gaffney FA, Inagami T. Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin IIinduced hypertension. Circulation 2001; 104: 346-51.
    • (2001) Circulation , vol.104 , pp. 346-351
    • Ichihara, S.1    Senbonmatsu, T.2    Price Jr., E.3    Ichiki, T.4    Gaffney, F.A.5    Inagami, T.6
  • 21
    • 0034991812 scopus 로고    scopus 로고
    • Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications
    • Carey RM, Jin XH, Siragy HM. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am J Hypertens 2001; 14: 98S-102S.
    • (2001) Am J Hypertens , vol.14
    • Carey, R.M.1    Jin, X.H.2    Siragy, H.M.3
  • 22
    • 0028010788 scopus 로고
    • Tissue angiotensin system in cardiovascular medicine. A paradigm shift
    • Dzau VJ, Re R. Tissue angiotensin system in cardiovascular medicine. A paradigm shift? Circulation 1994; 89: 493-8.
    • (1994) Circulation , vol.89 , pp. 493-498
    • Dzau, V.J.1    Re, R.2
  • 24
    • 0031736311 scopus 로고    scopus 로고
    • The renin-angiotensin system in the vessel wall
    • Muller DN, Luft FC. The renin-angiotensin system in the vessel wall. Basic Res Cardiol 1998; 93 (Suppl 2): 7-14.
    • (1998) Basic Res Cardiol , vol.93 , Issue.SUPPL. 2 , pp. 7-14
    • Muller, D.N.1    Luft, F.C.2
  • 25
    • 0023624502 scopus 로고
    • Tissue renin-angiotensin system: Sites of angiotensin formation
    • Campbell DJ. Tissue renin-angiotensin system: sites of angiotensin formation. J Cardiovasc Pharmacol 1987; 10 (Suppl 7): S1-8.
    • (1987) J Cardiovasc Pharmacol , vol.10 , Issue.SUPPL. 7
    • Campbell, D.J.1
  • 26
    • 0023120913 scopus 로고
    • Circulating and tissue angiotensin systems
    • Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6.
    • (1987) J Clin Invest , vol.79 , pp. 1-6
    • Campbell, D.J.1
  • 27
    • 0031016576 scopus 로고    scopus 로고
    • Myofibroblasts and local angiotensin II in rat cardiac tissue repair
    • Weber KT, Sun Y, Katwa LC. Myofibroblasts and local angiotensin II in rat cardiac tissue repair. Int J Biochem Cell Biol 1997; 29: 31-42.
    • (1997) Int J Biochem Cell Biol , vol.29 , pp. 31-42
    • Weber, K.T.1    Sun, Y.2    Katwa, L.C.3
  • 28
    • 0028012543 scopus 로고
    • Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence
    • von Lutterotti N, Catanzaro DF, Sealey JE, Laragh JH. Renin is not synthesized by cardiac and extrarenal vascular tissues. A review of experimental evidence. Circulation 1994; 89: 458-70.
    • (1994) Circulation , vol.89 , pp. 458-470
    • von Lutterotti, N.1    Catanzaro, D.F.2    Sealey, J.E.3    Laragh, J.H.4
  • 29
    • 42649088714 scopus 로고    scopus 로고
    • Renin and prorenin disappearance in humans post-nephrectomy: Evidence for binding?
    • Krop M, de Bruyn JH, Derkx FH, Danser AH. Renin and prorenin disappearance in humans post-nephrectomy: evidence for binding? Front Biosci 2008; 13: 3931-9.
    • (2008) Front Biosci , vol.13 , pp. 3931-3939
    • Krop, M.1    de Bruyn, J.H.2    Derkx, F.H.3    Danser, A.H.4
  • 30
    • 0025972262 scopus 로고
    • Molecular biology of the vascular reninangiotensin system
    • Samani NJ, Swales JD. Molecular biology of the vascular reninangiotensin system. Blood Vessels 1991; 28: 210-6.
    • (1991) Blood Vessels , vol.28 , pp. 210-216
    • Samani, N.J.1    Swales, J.D.2
  • 31
    • 0036266596 scopus 로고    scopus 로고
    • Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin
    • Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD. Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 2002; 109: 1417-27.
    • (2002) J Clin Invest , vol.109 , pp. 1417-1427
    • Nguyen, G.1    Delarue, F.2    Burckle, C.3    Bouzhir, L.4    Giller, T.5    Sraer, J.D.6
  • 32
    • 0037591344 scopus 로고    scopus 로고
    • Human prorenin has gate and handle regions for its non-proteolytic activation
    • Suzuki F, Hayakawa M, Nakagawa T, et al. Human prorenin has gate and handle regions for its non-proteolytic activation. J Biol Chem 2003; 278: 22217-22.
    • (2003) J Biol Chem , vol.278 , pp. 22217-22
    • Suzuki, F.1    Hayakawa, M.2    Nakagawa, T.3
  • 33
    • 0035834247 scopus 로고    scopus 로고
    • The relevance of tissue angiotensin-converting enzyme: Manifestations in mechanistic and endpoint data
    • Dzau VJ, Bernstein K, Celermajer D, et al. The relevance of tissue angiotensin-converting enzyme: manifestations in mechanistic and endpoint data. Am J Cardiol 2001; 88: 1L-20L.
    • (2001) Am J Cardiol , vol.88
    • Dzau, V.J.1    Bernstein, K.2    Celermajer, D.3
  • 34
    • 33845608395 scopus 로고    scopus 로고
    • A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein
    • Schefe JH, Menk M, Reinemund J, et al. A novel signal transduction cascade involving direct physical interaction of the renin/prorenin receptor with the transcription factor promyelocytic zinc finger protein. Circ Res 2006; 99: 1355-66.
    • (2006) Circ Res , vol.99 , pp. 1355-1366
    • Schefe, J.H.1    Menk, M.2    Reinemund, J.3
  • 35
    • 33750271641 scopus 로고    scopus 로고
    • The (pro)renin receptor: Therapeutic consequences
    • Nguyen G, Danser AH. The (pro)renin receptor: therapeutic consequences. Expert Opin Investig Drugs 2006; 15: 1131-5.
    • (2006) Expert Opin Investig Drugs , vol.15 , pp. 1131-1135
    • Nguyen, G.1    Danser, A.H.2
  • 36
    • 39749098706 scopus 로고    scopus 로고
    • Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide
    • Feldt S, Batenburg WW, Mazak I, et al. Prorenin and renin-induced extracellular signal-regulated kinase 1/2 activation in monocytes is not blocked by aliskiren or the handle-region peptide. Hypertension 2008; 51: 682-8.
    • (2008) Hypertension , vol.51 , pp. 682-688
    • Feldt, S.1    Batenburg, W.W.2    Mazak, I.3
  • 37
    • 33747050068 scopus 로고    scopus 로고
    • Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: Put the blame on the (pro)renin receptor?
    • Nguyen G. Increased cyclooxygenase-2, hyperfiltration, glomerulosclerosis, and diabetic nephropathy: put the blame on the (pro)renin receptor? Kidney Int 2006; 70: 618-20.
    • (2006) Kidney Int , vol.70 , pp. 618-620
    • Nguyen, G.1
  • 38
    • 33646160993 scopus 로고    scopus 로고
    • Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension
    • Ichihara A, Kaneshiro Y, Takemitsu T, et al. Nonproteolytic activation of prorenin contributes to development of cardiac fibrosis in genetic hypertension. Hypertension 2006; 47: 894-900.
    • (2006) Hypertension , vol.47 , pp. 894-900
    • Ichihara, A.1    Kaneshiro, Y.2    Takemitsu, T.3
  • 39
    • 55249108889 scopus 로고    scopus 로고
    • Activated prorenin as a therapeutic target for diabetic nephropathy
    • Ichihara A, Sakoda M, Mito-Kurauchi A, Itoh H. Activated prorenin as a therapeutic target for diabetic nephropathy. Diabetes Res Clin Pract 2008; 82 (Suppl 1): S63-6.
    • (2008) Diabetes Res Clin Pract , vol.82 , Issue.SUPPL. 1
    • Ichihara, A.1    Sakoda, M.2    Mito-Kurauchi, A.3    Itoh, H.4
  • 40
    • 62949147120 scopus 로고    scopus 로고
    • Diabetic complications: A role for the prorenin-(pro)renin receptor-TGF-beta1 axis?
    • van den Heuvel M, Batenburg WW, Danser AH. Diabetic complications: a role for the prorenin-(pro)renin receptor-TGF-beta1 axis? Mol Cell Endocrinol 2009; 302: 213-8.
    • (2009) Mol Cell Endocrinol , vol.302 , pp. 213-218
    • van den Heuvel, M.1    Batenburg, W.W.2    Danser, A.H.3
  • 41
    • 0027508388 scopus 로고
    • Non-angiotensin effects of angiotensinconverting enzyme inhibitors
    • Sunman W, Sever PS. Non-angiotensin effects of angiotensinconverting enzyme inhibitors. Clin Sci (Lond) 1993; 85: 661-70.
    • (1993) Clin Sci (Lond) , vol.85 , pp. 661-670
    • Sunman, W.1    Sever, P.S.2
  • 43
    • 0036452679 scopus 로고    scopus 로고
    • Angiotensin II inhibits renin gene transcription via the protein kinase C pathway
    • Muller MW, Todorov V, Kramer BK, Kurtz A. Angiotensin II inhibits renin gene transcription via the protein kinase C pathway. Pflugers Arch 2002; 444: 499-505.
    • (2002) Pflugers Arch , vol.444 , pp. 499-505
    • Muller, M.W.1    Todorov, V.2    Kramer, B.K.3    Kurtz, A.4
  • 44
    • 0028957020 scopus 로고
    • Commentary: Renin assays: A debate for clinicians, not only for specialists
    • Menard J, Guyene TT. Commentary: renin assays: a debate for clinicians, not only for specialists. J Hypertens 1995; 13: 367-9.
    • (1995) J Hypertens , vol.13 , pp. 367-369
    • Menard, J.1    Guyene, T.T.2
  • 45
    • 0023885367 scopus 로고
    • In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II
    • Nussberger J, Brunner DB, Waeber B, Brunner HR. In vitro renin inhibition to prevent generation of angiotensins during determination of angiotensin I and II. Life Sci 1988; 42: 1683-8.
    • (1988) Life Sci , vol.42 , pp. 1683-1688
    • Nussberger, J.1    Brunner, D.B.2    Waeber, B.3    Brunner, H.R.4
  • 46
    • 0023786558 scopus 로고
    • Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment
    • Laragh JH, Lamport B, Sealey J, Alderman MH. Diagnosis ex juvantibus. Individual response patterns to drugs reveal hypertension mechanisms and simplify treatment. Hypertension 1988; 12: 223-6.
    • (1988) Hypertension , vol.12 , pp. 223-226
    • Laragh, J.H.1    Lamport, B.2    Sealey, J.3    Alderman, M.H.4
  • 47
    • 0028278186 scopus 로고
    • Pharmacology of renin inhibitors and their application to the treatment of hypertension
    • Wood JM, Cumin F, Maibaum J. Pharmacology of renin inhibitors and their application to the treatment of hypertension. Pharmacol Ther 1994; 61: 325-44.
    • (1994) Pharmacol Ther , vol.61 , pp. 325-344
    • Wood, J.M.1    Cumin, F.2    Maibaum, J.3
  • 48
    • 0036372173 scopus 로고    scopus 로고
    • Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): Comparison with enalapril
    • Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 2002; 39: E1-8.
    • (2002) Hypertension , vol.39
    • Nussberger, J.1    Wuerzner, G.2    Jensen, C.3    Brunner, H.R.4
  • 50
    • 0029911431 scopus 로고    scopus 로고
    • Inappropriately high plasma renin activity accompanies chronic loss of renal function
    • Yeyati NL, Adrogue HJ. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am J Nephrol 1996; 16: 471-7.
    • (1996) Am J Nephrol , vol.16 , pp. 471-477
    • Yeyati, N.L.1    Adrogue, H.J.2
  • 51
    • 0033862643 scopus 로고    scopus 로고
    • Plasma renin activity in the emergency department and its independent association with acute myocardial infarction
    • Blumenfeld JD, Sealey JE, Alderman MH, et al. Plasma renin activity in the emergency department and its independent association with acute myocardial infarction. Am J Hypertens 2000; 13: 855-63.
    • (2000) Am J Hypertens , vol.13 , pp. 855-863
    • Blumenfeld, J.D.1    Sealey, J.E.2    Alderman, M.H.3
  • 52
    • 34547726196 scopus 로고    scopus 로고
    • Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension
    • Nussberger J, Gradman AH, Schmieder RE, Lins RL, Chiang Y, Prescott MF. Plasma renin and the antihypertensive effect of the orally active renin inhibitor aliskiren in clinical hypertension. Int J Clin Pract 2007; 61: 1461-8.
    • (2007) Int J Clin Pract , vol.61 , pp. 1461-1468
    • Nussberger, J.1    Gradman, A.H.2    Schmieder, R.E.3    Lins, R.L.4    Chiang, Y.5    Prescott, M.F.6
  • 53
    • 9644287897 scopus 로고    scopus 로고
    • Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption
    • Azizi M, Menard J, Bissery A, et al. Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption. J Am Soc Nephrol 2004; 15: 3126-33.
    • (2004) J Am Soc Nephrol , vol.15 , pp. 3126-3133
    • Azizi, M.1    Menard, J.2    Bissery, A.3
  • 54
    • 0033995775 scopus 로고    scopus 로고
    • Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure
    • Jorde UP, Ennezat PV, Lisker J, et al. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation 2000; 101: 844-6.
    • (2000) Circulation , vol.101 , pp. 844-846
    • Jorde, U.P.1    Ennezat, P.V.2    Lisker, J.3
  • 55
    • 28844457541 scopus 로고    scopus 로고
    • Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition
    • van de Wal RM, Plokker HW, Lok DJ, et al. Determinants of increased angiotensin II levels in severe chronic heart failure patients despite ACE inhibition. Int J Cardiol 2006; 106: 367-72.
    • (2006) Int J Cardiol , vol.106 , pp. 367-372
    • van de Wal, R.M.1    Plokker, H.W.2    Lok, D.J.3
  • 56
    • 0023571272 scopus 로고
    • Effects of converting-enzyme inhibitors on the reninangiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: Correlation of chemical structure and biologic activity
    • Zusman RM. Effects of converting-enzyme inhibitors on the reninangiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity. Am J Kidney Dis 1987; 10: 13-23.
    • (1987) Am J Kidney Dis , vol.10 , pp. 13-23
    • Zusman, R.M.1
  • 57
    • 0033028679 scopus 로고    scopus 로고
    • How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure?
    • MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD. How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 1999; 82: 57-61.
    • (1999) Heart , vol.82 , pp. 57-61
    • Macfadyen, R.J.1    Lee, A.F.2    Morton, J.J.3    Pringle, S.D.4    Struthers, A.D.5
  • 58
    • 0030096265 scopus 로고    scopus 로고
    • Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure
    • Struthers AD. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in chronic heart failure. J Card Fail 1996; 2: 47-54.
    • (1996) J Card Fail , vol.2 , pp. 47-54
    • Struthers, A.D.1
  • 59
    • 34548163060 scopus 로고    scopus 로고
    • The incidence and implications of aldosterone breakthrough
    • Bomback AS, Klemmer PJ. The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 2007; 3: 486-92.
    • (2007) Nat Clin Pract Nephrol , vol.3 , pp. 486-492
    • Bomback, A.S.1    Klemmer, P.J.2
  • 60
    • 0036314951 scopus 로고    scopus 로고
    • Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats
    • Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28-33.
    • (2002) Hypertension , vol.40 , pp. 28-33
    • Naruse, M.1    Tanabe, A.2    Sato, A.3
  • 61
    • 34047231332 scopus 로고    scopus 로고
    • Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: Is oral renin inhibition the solution?
    • Athyros VG, Mikhailidis DP, Kakafika AI, Tziomalos K, Karagiannis A. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007; 8: 529-35.
    • (2007) Expert Opin Pharmacother , vol.8 , pp. 529-535
    • Athyros, V.G.1    Mikhailidis, D.P.2    Kakafika, A.I.3    Tziomalos, K.4    Karagiannis, A.5
  • 62
    • 0000586975 scopus 로고
    • The preparation, purification, and amino acid sequence of a polypeptide renin substrate
    • Skeggs LT, Jr., Kahn JR, Lentz K, Shumway NP. The preparation, purification, and amino acid sequence of a polypeptide renin substrate. J Exp Med 1957; 106: 439-53.
    • (1957) J Exp Med , vol.106 , pp. 439-453
    • Skeggs Jr., L.T.1    Kahn, J.R.2    Lentz, K.3    Shumway, N.P.4
  • 63
    • 0024433356 scopus 로고
    • Renin inhibitors: Discovery and development. An overview and perspective
    • Kleinert HD. Renin inhibitors: discovery and development. An overview and perspective. Am J Hypertens 1989; 2: 800-8.
    • (1989) Am J Hypertens , vol.2 , pp. 800-808
    • Kleinert, H.D.1
  • 64
  • 65
    • 0042661157 scopus 로고    scopus 로고
    • Structure-based design of aliskiren, a novel orally effective renin inhibitor
    • Wood JM, Maibaum J, Rahuel J, et al. Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 2003; 308: 698-705.
    • (2003) Biochem Biophys Res Commun , vol.308 , pp. 698-705
    • Wood, J.M.1    Maibaum, J.2    Rahuel, J.3
  • 66
    • 43449133877 scopus 로고    scopus 로고
    • A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects
    • Limoges D, Dieterich HA, Yeh CM, Vaidyanathan S, Howard D, Dole WP. A study of dose-proportionality in the pharmacokinetics of the oral direct renin inhibitor aliskiren in healthy subjects. Int J Clin Pharmacol Ther 2008; 46: 252-8.
    • (2008) Int J Clin Pharmacol Ther , vol.46 , pp. 252-258
    • Limoges, D.1    Dieterich, H.A.2    Yeh, C.M.3    Vaidyanathan, S.4    Howard, D.5    Dole, W.P.6
  • 68
    • 33750357566 scopus 로고    scopus 로고
    • Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects
    • Vaidyanathan S, Jermany J, Yeh C, Bizot MN, Camisasca R. Aliskiren, a novel orally effective renin inhibitor, exhibits similar pharmacokinetics and pharmacodynamics in Japanese and Caucasian subjects. Br J Clin Pharmacol 2006; 62: 690-8.
    • (2006) Br J Clin Pharmacol , vol.62 , pp. 690-698
    • Vaidyanathan, S.1    Jermany, J.2    Yeh, C.3    Bizot, M.N.4    Camisasca, R.5
  • 69
    • 33947543780 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects
    • Vaidyanathan S, Reynolds C, Yeh CM, et al. Pharmacokinetics, safety, and tolerability of the novel oral direct renin inhibitor aliskiren in elderly healthy subjects. J Clin Pharmacol 2007; 47: 453-60.
    • (2007) J Clin Pharmacol , vol.47 , pp. 453-460
    • Vaidyanathan, S.1    Reynolds, C.2    Yeh, C.M.3
  • 70
    • 34547628374 scopus 로고    scopus 로고
    • Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment
    • Vaidyanathan S, Bigler H, Yeh C, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren alone and in combination with irbesartan in renal impairment. Clin Pharmacokinet 2007; 46: 661-75.
    • (2007) Clin Pharmacokinet , vol.46 , pp. 661-675
    • Vaidyanathan, S.1    Bigler, H.2    Yeh, C.3
  • 71
    • 33846456943 scopus 로고    scopus 로고
    • Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment
    • Vaidyanathan S, Warren V, Yeh C, Bizot MN, Dieterich HA, Dole WP. Pharmacokinetics, safety, and tolerability of the oral Renin inhibitor aliskiren in patients with hepatic impairment. J Clin Pharmacol 2007; 47: 192-200.
    • (2007) J Clin Pharmacol , vol.47 , pp. 192-200
    • Vaidyanathan, S.1    Warren, V.2    Yeh, C.3    Bizot, M.N.4    Dieterich, H.A.5    Dole, W.P.6
  • 72
    • 53349090037 scopus 로고    scopus 로고
    • Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers
    • Huang HL, Vaidyanathan S, Yeh CM, et al. Effect of aliskiren, an oral direct renin inhibitor, on the pharmacokinetics and pharmacodynamics of a single dose of acenocoumarol in healthy volunteers. Curr Med Res Opin 2008; 24: 2449-56.
    • (2008) Curr Med Res Opin , vol.24 , pp. 2449-2456
    • Huang, H.L.1    Vaidyanathan, S.2    Yeh, C.M.3
  • 73
    • 28044453329 scopus 로고    scopus 로고
    • Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine
    • Dieterle W, Corynen S, Vaidyanathan S, Mann J. Pharmacokinetic interactions of the oral renin inhibitor aliskiren with lovastatin, atenolol, celecoxib and cimetidine. Int J Clin Pharmacol Ther 2005; 43: 527-35.
    • (2005) Int J Clin Pharmacol Ther , vol.43 , pp. 527-535
    • Dieterle, W.1    Corynen, S.2    Vaidyanathan, S.3    Mann, J.4
  • 74
    • 54049086657 scopus 로고    scopus 로고
    • Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren
    • Vaidyanathan S, Camenisch G, Schuetz H, et al. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: the role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 2008; 48: 1323-38.
    • (2008) J Clin Pharmacol , vol.48 , pp. 1323-1338
    • Vaidyanathan, S.1    Camenisch, G.2    Schuetz, H.3
  • 75
    • 50149092635 scopus 로고    scopus 로고
    • A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects
    • Vaidyanathan S, Maboudian M, Warren V, et al. A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects. Curr Med Res Opin 2008; 24: 2313-26.
    • (2008) Curr Med Res Opin , vol.24 , pp. 2313-2326
    • Vaidyanathan, S.1    Maboudian, M.2    Warren, V.3
  • 76
    • 34247141847 scopus 로고    scopus 로고
    • Aliskiren (Tekturna) for hypertension
    • Aliskiren (Tekturna) for hypertension. Med Lett Drugs Ther 2007; 49: 29-31.
    • (2007) Med Lett Drugs Ther , vol.49 , pp. 29-31
  • 77
    • 0347479295 scopus 로고    scopus 로고
    • Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren
    • Stanton A, Jensen C, Nussberger J, O'Brien E. Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 2003; 42: 1137-43.
    • (2003) Hypertension , vol.42 , pp. 1137-1143
    • Stanton, A.1    Jensen, C.2    Nussberger, J.3    O'Brien, E.4
  • 78
    • 14844363404 scopus 로고    scopus 로고
    • Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebolike tolerability in hypertensive patients
    • Gradman AH, Schmieder RE, Lins RL, Nussberger J, Chiang Y, Bedigian MP. Aliskiren, a novel orally effective renin inhibitor, provides dose-dependent antihypertensive efficacy and placebolike tolerability in hypertensive patients. Circulation 2005; 111: 1012-8.
    • (2005) Circulation , vol.111 , pp. 1012-1018
    • Gradman, A.H.1    Schmieder, R.E.2    Lins, R.L.3    Nussberger, J.4    Chiang, Y.5    Bedigian, M.P.6
  • 79
    • 34447521458 scopus 로고    scopus 로고
    • Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomised, double-blind trial
    • Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 2007; 370: 221-9.
    • (2007) Lancet , vol.370 , pp. 221-229
    • Oparil, S.1    Yarows, S.A.2    Patel, S.3    Fang, H.4    Zhang, J.5    Satlin, A.6
  • 80
    • 34548855067 scopus 로고    scopus 로고
    • A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension
    • Strasser RH, Puig JG, Farsang C, Croket M, Li J, van Ingen H. A comparison of the tolerability of the direct renin inhibitor aliskiren and lisinopril in patients with severe hypertension. J Hum Hypertens 2007; 21: 780-7.
    • (2007) J Hum Hypertens , vol.21 , pp. 780-787
    • Strasser, R.H.1    Puig, J.G.2    Farsang, C.3    Croket, M.4    Li, J.5    van Ingen, H.6
  • 81
    • 39849089447 scopus 로고    scopus 로고
    • Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: A 6-month, randomized, double-blind trial
    • Andersen K, Weinberger MH, Egan B, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. J Hypertens 2008; 26: 589-99.
    • (2008) J Hypertens , vol.26 , pp. 589-599
    • Andersen, K.1    Weinberger, M.H.2    Egan, B.3
  • 82
    • 60549087324 scopus 로고    scopus 로고
    • Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: A 12-month randomized, double-blind comparator trial with hydrochlorothiazide
    • Schmieder RE, Philipp T, Guerediaga J, et al. Long-term antihypertensive efficacy and safety of the oral direct renin inhibitor aliskiren: a 12-month randomized, double-blind comparator trial with hydrochlorothiazide. Circulation 2009; 119: 417-25.
    • (2009) Circulation , vol.119 , pp. 417-425
    • Schmieder, R.E.1    Philipp, T.2    Guerediaga, J.3
  • 83
    • 67649763542 scopus 로고    scopus 로고
    • Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: Sub-analysis of a 52-week, randomized, doubleblind trial
    • Schmieder RE, Philipp T, Guerediaga J, Gorostidi M, Bush C, Keefe DL. Aliskiren-based therapy lowers blood pressure more effectively than hydrochlorothiazide-based therapy in obese patients with hypertension: sub-analysis of a 52-week, randomized, doubleblind trial. J Hypertens 2009; 27: 1493-501.
    • (2009) J Hypertens , vol.27 , pp. 1493-1501
    • Schmieder, R.E.1    Philipp, T.2    Guerediaga, J.3    Gorostidi, M.4    Bush, C.5    Keefe, D.L.6
  • 84
    • 33845366982 scopus 로고    scopus 로고
    • Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
    • Villamil A, Chrysant SG, Calhoun D, et al. Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide. J Hypertens 2007; 25: 217-26.
    • (2007) J Hypertens , vol.25 , pp. 217-226
    • Villamil, A.1    Chrysant, S.G.2    Calhoun, D.3
  • 85
    • 0019403812 scopus 로고
    • Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension
    • Lijnen P, Fagard R, Staessen J, Amery A. Effect of chronic diuretic treatment on the plasma renin-angiotensin-aldosterone system in essential hypertension. Br J Clin Pharmacol 1981; 12: 387-92.
    • (1981) Br J Clin Pharmacol , vol.12 , pp. 387-392
    • Lijnen, P.1    Fagard, R.2    Staessen, J.3    Amery, A.4
  • 86
    • 38349116979 scopus 로고    scopus 로고
    • [Last assessed August 17, 2009]
    • FDA Approves New Drug Treatment for High Blood Pressure. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108862.htm.[Last assessed August 17, 2009].
    • FDA Approves New Drug Treatment For High Blood Pressure
  • 87
    • 66149089653 scopus 로고    scopus 로고
    • Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone
    • Blumenstein M, Romaszko J, Calderon A, et al. Antihypertensive efficacy and tolerability of aliskiren/hydrochlorothiazide (HCT) single-pill combinations in patients who are non-responsive to HCT 25 mg alone. Curr Med Res Opin 2009; 25: 903-10.
    • (2009) Curr Med Res Opin , vol.25 , pp. 903-910
    • Blumenstein, M.1    Romaszko, J.2    Calderon, A.3
  • 89
    • 36248931230 scopus 로고    scopus 로고
    • Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy
    • Drummond W, Munger MA, Rafique EM, Maboudian M, Khan M, Keefe DL. Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 2007; 9: 742-50.
    • (2007) J Clin Hypertens (Greenwich) , vol.9 , pp. 742-750
    • Drummond, W.1    Munger, M.A.2    Rafique, E.M.3    Maboudian, M.4    Khan, M.5    Keefe, D.L.6
  • 91
    • 0033004196 scopus 로고    scopus 로고
    • Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the reninangiotensin-aldosterone system in normotensive and hypertensive subjects
    • Blumenfeld JD, Sealey JE, Mann SJ, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the reninangiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12: 451-9.
    • (1999) Am J Hypertens , vol.12 , pp. 451-459
    • Blumenfeld, J.D.1    Sealey, J.E.2    Mann, S.J.3
  • 92
    • 56749085787 scopus 로고    scopus 로고
    • Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1
    • Dietz R, Dechend R, Yu CM, et al. Effects of the direct renin inhibitor aliskiren and atenolol alone or in combination in patients with hypertension1. J Renin Angiotensin Aldosterone Syst 2008; 9: 163-75.
    • (2008) J Renin Angiotensin Aldosterone Syst , vol.9 , pp. 163-175
    • Dietz, R.1    Dechend, R.2    Yu, C.M.3
  • 93
    • 77952907194 scopus 로고    scopus 로고
    • [Last assessed August 17, 2009]
    • Combined Renin Inhibition/Beta-Blockade. Available at: http://www.clinicaltrials.gov/ct2/show/NCT00627861[Last assessed August 17, 2009].
    • Combined Renin Inhibition/Beta-Blockade
  • 94
    • 25444454353 scopus 로고    scopus 로고
    • Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats
    • Pilz B, Shagdarsuren E, Wellner M, et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in doubletransgenic rats. Hypertension 2005; 46: 569-76.
    • (2005) Hypertension , vol.46 , pp. 569-576
    • Pilz, B.1    Shagdarsuren, E.2    Wellner, M.3
  • 95
    • 46449118638 scopus 로고    scopus 로고
    • Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats
    • Feldman DL, Jin L, Xuan H, et al. Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 2008; 52: 130-6.
    • (2008) Hypertension , vol.52 , pp. 130-136
    • Feldman, D.L.1    Jin, L.2    Xuan, H.3
  • 96
    • 61349170589 scopus 로고    scopus 로고
    • Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy
    • Solomon SD, Appelbaum E, Manning WJ, et al. Effect of the direct Renin inhibitor aliskiren, the Angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy. Circulation 2009; 119: 530-7.
    • (2009) Circulation , vol.119 , pp. 530-537
    • Solomon, S.D.1    Appelbaum, E.2    Manning, W.J.3
  • 97
    • 79958249630 scopus 로고    scopus 로고
    • The Aliskiren Observation of Heart Failure Treatment. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure
    • McMurray JJV, Pitt B, Latini R, Maggioni AP, Solomon SD; for the Aliskiren Observation of Heart Failure Treatment. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail 2008; 1: 17-24.
    • (2008) Circ Heart Fail , vol.1 , pp. 17-24
    • McMurray, J.J.V.1    Pitt, B.2    Latini, R.3    Maggioni, A.P.4    Solomon, S.D.5
  • 99
    • 70349690296 scopus 로고    scopus 로고
    • Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria
    • Persson F, Rossing P, Reinhard H, et al. Renal effects of aliskiren compared to and in combination with irbesartan in patients with type 2 diabetes, hypertension and albuminuria. Diabetes Care 2009; 30: 1873-9.
    • (2009) Diabetes Care , vol.30 , pp. 1873-1879
    • Persson, F.1    Rossing, P.2    Reinhard, H.3
  • 101
    • 65249182083 scopus 로고    scopus 로고
    • Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): Rationale and study design
    • Parving HH, Brenner BM, McMurray JJ, et al. Aliskiren trial in type 2 diabetes using cardio-renal endpoints (ALTITUDE): rationale and study design. Nephrol Dial Transplant 2009; 24: 1663-71.
    • (2009) Nephrol Dial Transplant , vol.24 , pp. 1663-1671
    • Parving, H.H.1    Brenner, B.M.2    McMurray, J.J.3
  • 105
    • 57449100853 scopus 로고    scopus 로고
    • Aliskiren accumulates in Renin secretory granules and binds plasma prorenin
    • Krop M, Garrelds IM, de Bruin RJ, et al. Aliskiren accumulates in Renin secretory granules and binds plasma prorenin. Hypertension 2008; 52: 1076-83.
    • (2008) Hypertension , vol.52 , pp. 1076-1083
    • Krop, M.1    Garrelds, I.M.2    de Bruin, R.J.3
  • 106
    • 0034688194 scopus 로고    scopus 로고
    • Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
    • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-53.
    • (2000) N Engl J Med , vol.342 , pp. 145-153
    • Yusuf, S.1    Sleight, P.2    Pogue, J.3    Bosch, J.4    Davies, R.5    Dagenais, G.6
  • 107
    • 33746863179 scopus 로고    scopus 로고
    • Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials
    • Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006; 368: 581-8.
    • (2006) Lancet , vol.368 , pp. 581-588
    • Dagenais, G.R.1    Pogue, J.2    Fox, K.3    Simoons, M.L.4    Yusuf, S.5
  • 108
    • 42349086752 scopus 로고    scopus 로고
    • Renin inhibition by aliskiren prevents atherosclerosis progression: Comparison with irbesartan, atenolol, and amlodipine
    • Nussberger J, Aubert JF, Bouzourene K, Pellegrin M, Hayoz D, Mazzolai L. Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine. Hypertension 2008; 51: 1306-11.
    • (2008) Hypertension , vol.51 , pp. 1306-1311
    • Nussberger, J.1    Aubert, J.F.2    Bouzourene, K.3    Pellegrin, M.4    Hayoz, D.5    Mazzolai, L.6
  • 109
    • 40549106756 scopus 로고    scopus 로고
    • Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice
    • Lu H, Rateri DL, Feldman DL, Jr, et al. Renin inhibition reduces hypercholesterolemia-induced atherosclerosis in mice. J Clin Invest 2008; 118: 984-93.
    • (2008) J Clin Invest , vol.118 , pp. 984-993
    • Lu, H.1    Rateri, D.L.2    Feldman Jr., D.L.3
  • 110
    • 10344249378 scopus 로고    scopus 로고
    • Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists: Beyond the renin-angiotensin system
    • Kurtz TW, Pravenec M. Antidiabetic mechanisms of angiotensinconverting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. J Hypertens 2004; 22: 2253-61.
    • (2004) J Hypertens , vol.22 , pp. 2253-2261
    • Kurtz, T.W.1    Pravenec, M.2
  • 111
    • 51549101894 scopus 로고    scopus 로고
    • Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats
    • Rizzoni D, Pasini E, Flati V, et al. Angiotensin receptor blockers improve insulin signaling and prevent microvascular rarefaction in the skeletal muscle of spontaneously hypertensive rats. J Hypertens 2008; 26: 1595-601.
    • (2008) J Hypertens , vol.26 , pp. 1595-1601
    • Rizzoni, D.1    Pasini, E.2    Flati, V.3
  • 112
    • 77952947713 scopus 로고    scopus 로고
    • Are the pleiotropic effects of telmisartan clinically relevant?
    • Rizos CV, Elisaf MS, Liberopoulos EN. Are the pleiotropic effects of telmisartan clinically relevant? Curr Pharm Des 2009; 63: 1308-13.
    • (2009) Curr Pharm Des , vol.63 , pp. 1308-1313
    • Rizos, C.V.1    Elisaf, M.S.2    Liberopoulos, E.N.3
  • 113
    • 54349098473 scopus 로고    scopus 로고
    • Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat
    • Habibi J, Whaley-Connell A, Hayden MR, et al. Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology 2008; 149: 5643-53.
    • (2008) Endocrinology , vol.149 , pp. 5643-5653
    • Habibi, J.1    Whaley-Connell, A.2    Hayden, M.R.3
  • 114
    • 66649091226 scopus 로고    scopus 로고
    • Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression
    • Lastra G, Habibi J, Whaley-Connell AT, et al. Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology 2009; 150: 2561-8.
    • (2009) Endocrinology , vol.150 , pp. 2561-2568
    • Lastra, G.1    Habibi, J.2    Whaley-Connell, A.T.3
  • 116
    • 0033288410 scopus 로고    scopus 로고
    • Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPP) randomized trial
    • The Captopril Prevention Project (CAPP) Study Group
    • Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomized trial. The Captopril Prevention Project (CAPP) Study Group. Curr Hypertens Rev 1999; 1: 466-7.
    • (1999) Curr Hypertens Rev , vol.1 , pp. 466-467
  • 117
    • 0037160968 scopus 로고    scopus 로고
    • Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol
    • Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
    • (2002) Lancet , vol.359 , pp. 995-1003
    • Dahlof, B.1    Devereux, R.B.2    Kjeldsen, S.E.3
  • 118
    • 2942635317 scopus 로고    scopus 로고
    • Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial
    • Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363: 2022-31.
    • (2004) Lancet , vol.363 , pp. 2022-2031
    • Julius, S.1    Kjeldsen, S.E.2    Weber, M.3
  • 119
    • 38949084591 scopus 로고    scopus 로고
    • Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    • Black HR, Davis B, Barzilay J, et al. Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008; 31: 353-60.
    • (2008) Diabetes Care , vol.31 , pp. 353-360
    • Black, H.R.1    Davis, B.2    Barzilay, J.3
  • 120
    • 33749590988 scopus 로고    scopus 로고
    • Effect of ramipril on the incidence of diabetes
    • Bosch J, Yusuf S, Gerstein HC, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med 2006; 355: 1551-62.
    • (2006) N Engl J Med , vol.355 , pp. 1551-1562
    • Bosch, J.1    Yusuf, S.2    Gerstein, H.C.3
  • 121
    • 29144477713 scopus 로고    scopus 로고
    • Preventing type 2 diabetes in high risk patients: An overview of lifestyle and pharmacological measures
    • Liberopoulos EN, Tsouli S, Mikhailidis DP, Elisaf MS. Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures. Curr Drug Targets 2006; 7: 211-28.
    • (2006) Curr Drug Targets , vol.7 , pp. 211-228
    • Liberopoulos, E.N.1    Tsouli, S.2    Mikhailidis, D.P.3    Elisaf, M.S.4
  • 122
    • 24644510705 scopus 로고    scopus 로고
    • Long-term effects of ramipril on cardiovascular events and on diabetes: Results of the HOPE study extension
    • Bosch J, Lonn E, Pogue J, Arnold JM, Dagenais GR, Yusuf S. Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. Circulation 2005; 112: 1339-46.
    • (2005) Circulation , vol.112 , pp. 1339-1346
    • Bosch, J.1    Lonn, E.2    Pogue, J.3    Arnold, J.M.4    Dagenais, G.R.5    Yusuf, S.6
  • 123
    • 52949093903 scopus 로고    scopus 로고
    • Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial
    • Califf RM, Boolell M, Haffner SM, et al. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Am Heart J 2008; 156: 623-32.
    • (2008) Am Heart J , vol.156 , pp. 623-632
    • Califf, R.M.1    Boolell, M.2    Haffner, S.M.3
  • 124
    • 33947182655 scopus 로고    scopus 로고
    • Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension
    • Oh BH, Mitchell J, Herron JR, Chung J, Khan M, Keefe DL. Aliskiren, an oral renin inhibitor, provides dose-dependent efficacy and sustained 24-hour blood pressure control in patients with hypertension. J Am Coll Cardiol 2007; 49: 1157-63.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1157-1163
    • Oh, B.H.1    Mitchell, J.2    Herron, J.R.3    Chung, J.4    Khan, M.5    Keefe, D.L.6
  • 125
    • 75149195876 scopus 로고    scopus 로고
    • Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: Results of a randomized, double-blind study
    • Palatini P, Jung W, Shlyakhto E, Botha J, Bush C, Keefe DL. Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study. J Hum Hypertens 2010; 24: 93-103.
    • (2010) J Hum Hypertens , vol.24 , pp. 93-103
    • Palatini, P.1    Jung, W.2    Shlyakhto, E.3    Botha, J.4    Bush, C.5    Keefe, D.L.6
  • 126
    • 27544463207 scopus 로고    scopus 로고
    • Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis
    • Lindholm LH, Carlberg B, Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366: 1545-53.
    • (2005) Lancet , vol.366 , pp. 1545-1553
    • Lindholm, L.H.1    Carlberg, B.2    Samuelsson, O.3
  • 127
    • 33748650250 scopus 로고    scopus 로고
    • New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society
    • Sever P. New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. J Renin Angiotensin Aldosterone Syst 2006; 7: 61-3.
    • (2006) J Renin Angiotensin Aldosterone Syst , vol.7 , pp. 61-63
    • Sever, P.1
  • 128
    • 35948950676 scopus 로고    scopus 로고
    • Plasma renin and risk of cardiovascular disease and mortality: The Framingham Heart Study
    • Parikh NI, Gona P, Larson MG, et al. Plasma renin and risk of cardiovascular disease and mortality: the Framingham Heart Study. Eur Heart J 2007; 28: 2644-52.
    • (2007) Eur Heart J , vol.28 , pp. 2644-2652
    • Parikh, N.I.1    Gona, P.2    Larson, M.G.3
  • 129
    • 33845709506 scopus 로고    scopus 로고
    • Multiple biomarkers for the prediction of first major cardiovascular events and death
    • Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med 2006; 355: 2631-9.
    • (2006) N Engl J Med , vol.355 , pp. 2631-2639
    • Wang, T.J.1    Gona, P.2    Larson, M.G.3
  • 130
    • 34247644329 scopus 로고    scopus 로고
    • Aliskiren, the first renin inhibitor for treating hypertension: Reactive renin secretion may limit its effectiveness
    • Sealey JE, Laragh JH. Aliskiren, the first renin inhibitor for treating hypertension: reactive renin secretion may limit its effectiveness. Am J Hypertens 2007; 20: 587-97.
    • (2007) Am J Hypertens , vol.20 , pp. 587-597
    • Sealey, J.E.1    Laragh, J.H.2
  • 131
    • 34548442794 scopus 로고    scopus 로고
    • The difficult conception, birth and delivery of a renin inhibitor: Controversies around aliskiren
    • Menard J, Azizi M. The difficult conception, birth and delivery of a renin inhibitor: controversies around aliskiren. J Hypertens 2007; 25: 1775-82.
    • (2007) J Hypertens , vol.25 , pp. 1775-1782
    • Menard, J.1    Azizi, M.2
  • 133
    • 37349091464 scopus 로고    scopus 로고
    • Interpretation of plasma renin concentration in patients receiving aliskiren therapy
    • Campbell DJ. Interpretation of plasma renin concentration in patients receiving aliskiren therapy. Hypertension 2008; 51: 15-8.
    • (2008) Hypertension , vol.51 , pp. 15-18
    • Campbell, D.J.1
  • 134
    • 44849107992 scopus 로고    scopus 로고
    • Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells
    • Batenburg WW, de Bruin RJ, van Gool JM, et al. Aliskiren-binding increases the half life of renin and prorenin in rat aortic vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2008; 28: 1151-7.
    • (2008) Arterioscler Thromb Vasc Biol , vol.28 , pp. 1151-1157
    • Batenburg, W.W.1    de Bruin, R.J.2    van Gool, J.M.3
  • 135
    • 65949116587 scopus 로고    scopus 로고
    • Activity assays and immunoassays for plasma Renin and prorenin: Information provided and precautions necessary for accurate measurement
    • Campbell DJ, Nussberger J, Stowasser M, et al. Activity assays and immunoassays for plasma Renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009; 55: 867-77.
    • (2009) Clin Chem , vol.55 , pp. 867-877
    • Campbell, D.J.1    Nussberger, J.2    Stowasser, M.3
  • 136
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-59.
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2    Pogue, J.3
  • 137
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
    • Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008; 372: 547-53.
    • (2008) Lancet , vol.372 , pp. 547-553
    • Mann, J.F.1    Schmieder, R.E.2    McQueen, M.3
  • 138
    • 34648814214 scopus 로고    scopus 로고
    • Dual inhibition of the renin system by aliskiren and valsartan
    • Oparil S, Yarows SA, Patel S, Zhang J, Satlin A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007; 370: 1126-7.
    • (2007) Lancet , vol.370 , pp. 1126-1127
    • Oparil, S.1    Yarows, S.A.2    Patel, S.3    Zhang, J.4    Satlin, A.5
  • 139
    • 69849114573 scopus 로고    scopus 로고
    • Aliskiren and valsartan in stage 2 hypertension: Subgroup analysis of a randomized, double-blind study
    • Yarows SA, Oparil S, Patel S, Fang H, Zhang J. Aliskiren and valsartan in stage 2 hypertension: subgroup analysis of a randomized, double-blind study. Adv Ther 2008; 25: 1288-302.
    • (2008) Adv Ther , vol.25 , pp. 1288-1302
    • Yarows, S.A.1    Oparil, S.2    Patel, S.3    Fang, H.4    Zhang, J.5
  • 140
    • 0030806988 scopus 로고    scopus 로고
    • Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: Prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction
    • Tsutamoto T, Wada A, Maeda K, et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation 1997; 96: 509-16.
    • (1997) Circulation , vol.96 , pp. 509-516
    • Tsutamoto, T.1    Wada, A.2    Maeda, K.3
  • 141
    • 67650451498 scopus 로고    scopus 로고
    • Proteinuria as a surrogate outcome in CKD: Report of a scientific workshop sponsored by the national kidney foundation and the us food and drug administration
    • Levey AS, Cattran D, Friedman A, et al. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the national kidney foundation and the us food and drug administration. Am J Kidney Dis 2009; 54: 205-26.
    • (2009) Am J Kidney Dis , vol.54 , pp. 205-226
    • Levey, A.S.1    Cattran, D.2    Friedman, A.3
  • 142
    • 69249202278 scopus 로고    scopus 로고
    • Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively
    • Stanton AV, Dicker P, O'Brien ET. Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively. Am J Hypertens 2009; 22: 954-7.
    • (2009) Am J Hypertens , vol.22 , pp. 954-957
    • Stanton, A.V.1    Dicker, P.2    O'Brien, E.T.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.